Your browser doesn't support javascript.
loading
Management of allergic rhinitis improves clinical outcomes of difficult-to-treat tic disorders or attention-deficit/hyperactivity disorders.
Yu, Rui-Li; Wang, Jing; Wang, Xue-Song; Wang, Hong-Tian; Wang, Xue-Yan.
Afiliação
  • Yu RL; Department of Allergy, Beijing Shijitan Hospital, Capital Medical University.
  • Wang J; Department of Pediatrics, First Medical Center, PLA General Hospital, Beijing, and.
  • Wang XS; Department of Otolaryngology, Binzhou Central Hospital Affiliated to Binzhou Medical College, Binzhou, Shandong, China.
  • Wang HT; Department of Allergy, Beijing Shijitan Hospital, Capital Medical University.
  • Wang XY; Department of Allergy, Beijing Shijitan Hospital, Capital Medical University.
Allergol Select ; 7: 191-197, 2023.
Article em En | MEDLINE | ID: mdl-37881681
ABSTRACT

AIMS:

This case series aimed to evaluate the effects of treatment for allergic rhinitis (AR) in AR-diagnosed children with previous diagnosis of tic disorders/attention-deficit/hyperactivity disorders (TD/ADHD) but unresponsive to behavioral or medical treatment. MATERIALS AND

METHODS:

Between July 2016 and June 2021, children diagnosed with AR in our hospital were enrolled. All were diagnosed with TD/ADHD refractory to behavioral or medical treatment. The demography and clinical information were collected from medical records. The outcomes were visual analogue scale (VAS) for AR severity, Yale Comprehensive Tic Severity Scale (YGTSS) for TD symptoms, and Attention-Deficit Hyperactivity Screening Scale (SNAP-IV) for ADHD symptoms.

RESULTS:

A total of 27 children (18 boys, 9 girls) were included, with a mean age 7.4 ± 2.9 years (3 - 17 years). They had undergone behavioral or medical treatment of TD/ADHD for 3.6 ± 1.9 years but without significant improvement in TD/ADHD symptoms. After 2-6 months of systematic treatment for AR, VAS was decreased to 0.4 ± 0.1 from 0.8 ± 0.2, YGTSS to 3.5 ± 0.7 from 6.8 ± 1.4, and SNAP-IV to 0.4 ± 0.1 from 0.6 ± 0.2 (all p < 0.001). No recurrence of TD/ADHD symptoms was reported during a mean follow-up of 2.4 ± 1.1 years (0.5 - 5 years).

CONCLUSION:

AR treatment improves TD/ADHD outcomes in children with difficult-to-treat TD/ADHD. In TD/ADHD children who are unresponsive to behavioral or drug treatment and have AR-related symptoms, AR examination and treatment are recommended for better prognosis.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Allergol Select Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Allergol Select Ano de publicação: 2023 Tipo de documento: Article
...